TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
Authors:
- Elise F. NassifElise F. Nassif
- Edouard AuclinEAEdouard Auclin
- Rastilav BahledaRBRastilav Bahleda
- Charles HonoréCHCharles Honoré
- Olivier MirOMOlivier Mir
- Sarah DumontSDSarah Dumont
- Benoite MeryBMBenoite Mery
- Khalil HodrojKHKhalil Hodroj
- Mehdi BrahmiMBMehdi Brahmi
- Olivier TrédanOTOlivier Trédan
- Isabelle Ray-CoquardIRIsabelle Ray-Coquard
- Jean-Yves BlayJean-Yves Blay
Open Access
Abstract
(1) Background: locally resected high-grade sarcomas relapse in 40% of cases. There is no prognostic or predictive genomic marker for response to peri-operative chemotherapy. (2) Methods: MOSCATO and ProfiLER are pan-tumor prospective precision medicine trials for advanced tumors. Molecular analysis in both trials comprised targeted next-generation sequencing and comparative genomic hybridization array. We investigated if molecular alterations identified in these trials in sarcomas were associated with disease-free survival (DFS) and response to anthracyclines. (3) Results: this analysis included 215 sarcomas, amongst which 53 leiomyosarcomas, 27 rhabdomyosarcomas, 20 undifferentiated pleomorphic sarcomas, and 17 liposarcomas. The most frequently altered gene was TP53 (46 mutations and eight deletions). There were 149 surgically resected localized sarcomas. Median DFS in TP53 wild type (WT), deleted, and mutated sarcomas was 16, 10, and 10 months, respectively (p = 0.028; deletions: HR = 1.55; 95% CI = 0.75–3.19; mutations: HR = 1.70; 95%CI = 1.13–2.64). In multivariate analysis, TP53 mutations remained associated with shorter DFS (p = 0.027; HR = 2.30; 95%CI = 1.10–4.82). There were 161 localized and advanced sarcomas evaluable for response to anthracyclines. Objective response rates were 35% and 55% in TP53 WT and mutated sarcomas, respectively (OR = 2.24; 95%CI = 1.01–5.03; p = 0.05). In multivariate analysis, TP53 mutations remained associated with increased response (OR = 3.24; 95%CI = 1.30–8.45; p = 0.01). (4) Conclusions: TP53 mutations are associated with shorter DFS and increased response to anthracyclines. Post-validation, these findings could assist in decision-making for peri-operative treatments.Keywords
This publication has 41 references indexed in Scilit:
- Value of TP53 Status for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Meta-AnalysisPLOS ONE, 2012
- Attenuation of Soft-Tissue Sarcomas Resistance to the Cytotoxic Action of TNF-α by Restoring p53 FunctionPLOS ONE, 2012
- p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast CancerCancer Cell, 2012
- Prognostic and predictive value of TP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trialBreast Cancer Research, 2012
- Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomasEuropean Journal of Cancer, 2011
- Mutant p53 Drives Invasion by Promoting Integrin RecyclingCell, 2009
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI: Journal of the National Cancer Institute, 2009
- p53 dependent cell‐cycle arrest triggered by chemotherapy in xenografted breast tumorsInternational Journal of Cancer, 2008
- Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)JNCI: Journal of the National Cancer Institute, 2005
- Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading systemInternational Journal of Cancer, 1984